Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2010, for Excaliber Enterprises, Ltd. (Note: The input metadata referenced "Vistagen Therapeutics," but the filing text explicitly identifies the registrant as Excaliber Enterprises, Ltd.). The company is a Nevada corporation classified as a Development Stage Company and a Shell Company. Its stated business is selling specialty gift baskets to health care professionals, organizations, patients, and real estate agents. As of the reporting date, the company had no revenues and limited operations.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2010 | Three Months Ended Mar 31, 2009 | Cumulative (Inception to Mar 31, 2010) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Total Expenses | $2,774 | $17,189 | $51,343 |
| Net Loss | $(2,804) | $(17,219) | $(51,463) |
| Cash Balance (Ending) | $3,544 | $3,852 | N/A |
| Total Assets | $4,257 | N/A | N/A |
| Total Liabilities | $4,185 | N/A | N/A |
| Stockholders' Equity | $72 | N/A | N/A |
Debt and Liquidity: Current liabilities include $3,655 in accounts payable, a $30 note payable to a third party, and a $500 note payable to a related party. The company has a $20,000 revolving line of credit secured in August 2009, but $0 has been drawn as of March 31, 2010.
Material Changes vs. Prior Period
- Expense Reduction: Total expenses for the quarter dropped significantly from $17,189 in Q1 2009 to $2,774 in Q1 2010. This decrease was driven primarily by a reduction in general and administrative expenses from $17,082 to $2,667.
- Net Loss Improvement: The net loss narrowed from $(17,219) in the prior year quarter to $(2,804) in the current quarter.
- Liabilities: Accounts payable increased from $1,000 (Dec 31, 2009) to $3,655 (Mar 31, 2010), indicating an accumulation of unpaid vendor obligations.
- Cash Position: Cash on hand increased slightly from $556 at the end of 2009 to $3,544 at the end of Q1 2010, largely due to a $3,000 cash donation from an officer/director and a $30 loan.
Outlook, Risks, and Management Commentary
Going Concern: The filing explicitly states that the company's ability to continue as a going concern is in doubt. Management believes current cash ($3,544) is insufficient to fund operations for the next 12 months. The company is dependent on securing additional equity or debt financing.
Plan of Operation: Management intends to utilize the $20,000 line of credit to:
- Improve the company website with e-commerce functionality (budgeted up to $6,000).
- Implement web advertising campaigns (budgeted up to $10,000).
- Pursue direct sales efforts (budgeted up to $2,000).
Risks and Contingencies:
- Internal Controls: Management identified a material weakness in internal controls due to the lack of a functioning audit committee and a lack of independent outside directors.
- Revenue Uncertainty: Despite receiving informal inquiries, the company has generated no revenue since inception. There is no assurance that the new strategy will generate sales.
- Related Party Dependence: The company relies heavily on officers and directors for donated capital, free office space, and services.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Vistagen Therapeutics") and the actual filing registrant ("Excaliber Enterprises, Ltd.").
- Confirm the status of the $20,000 line of credit and whether any funds have been drawn since the filing date.
- Assess the company's ability to service its $3,655 in accounts payable given the minimal cash balance of $3,544.
- Review the progress of the website redesign and e-commerce implementation as the primary revenue driver.
- Monitor for any new equity issuances or debt financings required to address the "substantial doubt" regarding the going concern status.